Roivant Sciences Ltd (ROIV)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $28.64B
Last updated: Nov 17, 2026 at 11:06 AM ET
Roivant Sciences Ltd (ROIV) Financials: Revenue, Profit and Cash Flow
Roivant Sciences reported revenue of $8.26M for the fiscal year ended Mar 31, 2026, down 71.6% from the year before. That year, net income was -$397.91M with a net margin of -4817.3%, operating cash flow was -$750.35M and free cash flow was -$758.56M. The quarter ended Sep 30, 2026 had revenue of $35.12M and net income of -$137.21M.
Revenue and Margins
Over the 7 years to Mar 2026, revenue grew from $2.32M, a compound annual rate of 19.9%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Mar 2026 | $8.26M | -71.6% | 100.0% | -6235.7% | -4817.3% |
| Mar 2025 | $29.05M | -11.2% | 100.0% | -3453.3% | -1227.9% |
| Mar 2024 | $32.71M | +3.8% | 100.0% | 13746.9% | 12934.3% |
| Mar 2023 | $31.53M | -43.0% | 100.0% | -2875.9% | -3537.8% |
| Mar 2022 | $55.29M | +132.3% | 100.0% | -2444.8% | -1671.5% |
| Mar 2021 | $23.80M | -64.8% | 100.0% | -4500.5% | -3783.3% |
| Mar 2020 | $67.69M | +2812.6% | 98.3% | -786.6% | 1773.6% |
| Mar 2019 | $2.32M | N/A | 73.9% | -32207.0% | -44835.2% |
Income Statement
In the fiscal year ended Mar 2026, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.26M | $29.05M | $32.71M | $31.53M | $55.29M | $23.80M | $67.69M | $2.32M |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $1.13M | $606.00K |
| Gross profit | $8.26M | $29.05M | $32.71M | $31.53M | $55.29M | $23.80M | $66.56M | $1.72M |
| Research and development | $681.81M | $550.41M | $466.36M | $551.81M | $622.93M | $832.76M | $263.22M | $512.99M |
| Operating income | -$515.07M | -$1.00B | $4.50B | -$906.76M | -$1.35B | -$1.07B | -$532.42M | -$748.49M |
| Net income | -$397.91M | -$356.73M | $4.23B | -$1.12B | -$924.12M | -$900.23M | $1.20B | -$1.04B |
| EBITDA | N/A | N/A | N/A | N/A | -$1.27B | N/A | N/A | $138.13M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35.12M | $1.44M | $2.52M | $2.00M | $1.57M | $2.17M | $7.57M | $9.02M | $4.47M | $7.99M | -$8.12M | $15.56M |
| Gross profit | $31.77M | $1.44M | $2.67M | $2.00M | $1.46M | $2.17M | $7.78M | $9.02M | $4.47M | $7.78M | -$8.12M | $15.56M |
| Operating income | -$268.05M | -$365.99M | $415.24M | -$339.15M | -$306.23M | -$284.92M | -$284.96M | -$274.38M | -$341.71M | -$102.23M | -$140.12M | $5.13B |
| Net income | -$137.21M | -$290.61M | $355.74M | -$313.70M | -$166.04M | -$273.91M | -$252.38M | $118.08M | -$279.92M | $57.49M | -$182.50M | $5.07B |
Balance Sheet
As of Mar 2026, cash and equivalents exceeded short-term debt of $11.15M by $1.41B.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $5.71B | $5.44B | $7.22B | $2.39B | $2.59B | $2.59B | $2.48B | $1.39B |
| Current assets | $5.17B | $5.00B | $6.73B | $1.80B | $2.15B | $2.19B | $2.22B | $1.19B |
| Cash and equivalents | $1.42B | $2.72B | $6.49B | $1.68B | $2.06B | $2.06B | $2.19B | $849.55M |
| Total liabilities | $416.27M | $249.74M | $773.95M | $782.02M | $523.70M | $527.69M | $368.36M | $450.51M |
| Short-term debt | $11.15M | $9.84M | $21.89M | $40.72M | $0 | $12.31M | $7.84M | $21.18M |
| Long-term debt | N/A | N/A | $430.59M | $375.51M | $210.03M | $170.28M | N/A | N/A |
| Shareholder equity | $4.53B | $4.69B | $5.97B | $1.16B | $1.66B | $1.80B | $2.03B | $937.30M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $4.98B | $5.31B | $5.73B | $5.23B | $5.06B | $5.03B | $5.44B | $5.79B | $6.21B | $6.50B | $7.22B | $7.31B |
| Total liabilities | $380.10M | $384.62M | $435.63M | $251.14M | $257.14M | $216.70M | $249.74M | $256.38M | $625.99M | $601.16M | $773.95M | $728.10M |
| Cash and equivalents | $1.64B | $1.25B | $1.42B | $1.48B | $1.24B | $1.24B | $2.72B | $1.99B | $1.96B | $5.68B | $6.54B | $6.67B |
| Shareholder equity | $4.02B | $4.23B | $4.53B | $4.27B | $4.36B | $4.35B | $4.69B | $5.19B | $5.15B | $5.44B | $5.97B | $6.09B |
Cash Flow
Operating cash flow was negative in the fiscal year ended Mar 2026.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$750.35M | -$839.45M | -$765.27M | -$843.39M | -$677.73M | -$552.14M | -$761.83M | -$1.02B |
| Capital expenditures | $8.21M | $4.60M | $1.38M | $12.69M | $17.44M | $5.81M | $4.92M | $11.40M |
| Free cash flow | -$758.56M | -$844.05M | -$766.65M | -$856.08M | -$695.16M | -$557.94M | -$766.75M | -$1.04B |
| Dividends paid | $0 | $0 | $6.00M | $0 | N/A | N/A | N/A | N/A |
| Share repurchases | $319.50M | $1.29B | $0 | $0 | N/A | N/A | N/A | N/A |
| Investing cash flow | -$682.33M | -$1.77B | $5.20B | -$44.27M | $303.30M | -$31.70M | $1.69B | -$57.61M |
| Financing cash flow | $134.24M | -$1.22B | $419.36M | $499.46M | $306.79M | $456.26M | $217.16M | $767.02M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $594.42M | -$270.50M | -$163.82M | -$196.48M | -$185.66M | -$204.38M | -$172.56M | -$207.25M | -$266.81M | -$192.83M | -$108.46M | -$210.45M |
| Capital expenditures | $208.00K | $419.00K | $1.26M | $4.93M | $7.85M | $4.04M | $811.00K | $1.83M | $996.00K | $965.00K | $349.00K | $355.00K |
| Free cash flow | $594.21M | -$270.92M | -$165.08M | -$201.42M | -$193.51M | -$208.42M | -$173.38M | -$209.08M | -$267.80M | -$193.79M | -$108.81M | -$210.81M |
Frequently Asked Questions About ROIV
What is Roivant Sciences' annual revenue?
Roivant Sciences reported revenue of $8.26M for the fiscal year ended Mar 31, 2026.
How fast is Roivant Sciences' revenue growing?
Revenue was down 71.6% for the fiscal year ended Mar 31, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was -36.0%.
Is Roivant Sciences profitable?
No. Roivant Sciences reported net income of -$397.91M for the fiscal year ended Mar 31, 2026, with a net margin of -4817.3%.
How much free cash flow does ROIV generate?
For the fiscal year ended Mar 31, 2026, operating cash flow of -$750.35M minus capital expenditures of $8.21M produced free cash flow of -$758.56M.
How much debt does Roivant Sciences have?
The balance sheet dated Mar 31, 2026 reported short-term debt of $11.15M and cash and equivalents of $1.42B.
ROIV pages: Overview, Earnings, Forecast, Financials, Competitors